GENETIC SUSCEPTIBILITY TO LUNG CANCER

肺癌的遗传易感性

基本信息

项目摘要

It is becoming increasingly evident that the etiology of lung cancer involves a combination of both environmental and hereditary factors and that individuals may vary substantially in their genetic susceptibility to carcinogens such as tobacco. The primary goal of this project is to identify individuals genetically predisposed to be at very high risk. To do so we will establish a population-based lung cancer registry consisting of approximately 2 million. We will collect demographic, family history, and smoking data on lung cancer patients and family members. Blood samples will be collected and stored in conjunction with the SPORE Pathology Resource Core (Core B). We will perform segregation analysis on these families to fit genetic and environmental hypotheses and determine the best model characterizing familial aggregation of lung cancer (Aim 1). In doing so, we will also identify specific kindreds which will be useful for subsequent genetic linkage and candidate gene studies. Proband clinical characteristics which may be associated with increased cancer risk to family members will be determined. Sensitivity of peripheral blood lymphocyte DNA to mutagen-induced chromatid breaks will be assessed in lung cancer patients with an without a family history of lung cancer (Aim 2). In addition, we will compare patterns of allele loss in lung cancers from lung cancer patients with a family history of lung cancer and will determine if different patterns of allele loss occur in familial tumors (Aim 3). This part of the project will be closely integrated with Project #3, Molecular Markers for Early Lung Cancer Detection and Project 1, Identification of 3p Recessive Oncogenes in Lung Cancer. Moreover, this project could interact closely with Developmental Project 1 in determining patterns of potential inherited predisposition to nicotine dependency within lung cancer prone families. In addition to addressing the Specific Aims, one of the most important translational applications of this proposal will be the identification of a cohort of asymptomatic individuals who, because of a genetic predisposition, may be candidates for future development of lung cancer chemoprevention trials, a goal of Project #4, or the development of early detection strategies, a goal of Project #3.
肺癌的病因学越来越明显, 涉及环境和遗传因素的结合, 个体的遗传易感性可能会有很大的差异, 致癌物质,如烟草。 该项目的主要目标是 确定在遗传上有极高风险倾向的个体。 为此,我们将建立一个以人口为基础的肺癌登记处 约有200万人。 我们将收集人口统计数据, 肺癌患者和家庭的家族史和吸烟数据 成员血液样本的采集和储存将与 SPORE病理学资源核心(核心B)。我们将执行隔离 对这些家庭进行分析,以符合遗传和环境假设 并确定表征肺的家族聚集性的最佳模型 癌症(目标1)。在此过程中,我们还将确定特定的kinematic 这将有助于后续的遗传连锁和候选基因 问题研究 可能与以下疾病相关的先证者临床特征 将确定家庭成员患癌症的风险增加。 灵敏度 外周血淋巴细胞DNA对诱变剂诱导的染色单体断裂的影响 将在没有家庭的肺癌患者中进行评估 肺癌病史(目标2)。 此外,我们将比较模式 来自有家族史的肺癌患者的肺癌等位基因丢失 肺癌的历史,并将确定是否有不同的模式, 等位基因丢失发生在家族性肿瘤中(Aim 3)。这部分项目 将与项目#3紧密结合,早期分子标记 肺癌检测和项目1,3p隐性基因的鉴定 肺癌中的癌基因 此外,该项目可以密切互动, 与发展项目1在确定模式的潜力 肺癌易感人群中尼古丁依赖的遗传易感性 家庭 除了具体目标外,最重要的目标之一是 这一建议的翻译应用将是识别 一群无症状的个体,由于遗传原因, 易感性,可能是未来发展肺癌的候选人 化学预防试验,项目#4的目标,或开发 早期检测策略,项目#3的目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GAIL ELIZABETH TOMLINSON其他文献

GAIL ELIZABETH TOMLINSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GAIL ELIZABETH TOMLINSON', 18)}}的其他基金

Correlative Genetic Markers in Childhood Hepatoblastoma
儿童肝母细胞瘤的相关遗传标记
  • 批准号:
    7471992
  • 财政年份:
    2008
  • 资助金额:
    $ 13.22万
  • 项目类别:
Correlative Genetic Markers in Childhood Hepatoblastoma
儿童肝母细胞瘤的相关遗传标记
  • 批准号:
    7694974
  • 财政年份:
    2008
  • 资助金额:
    $ 13.22万
  • 项目类别:
Serum Markers of Angiogenesis in von Hippel-Lindau Dise*
希佩尔-林道病血管生成的血清标志物*
  • 批准号:
    6891040
  • 财政年份:
    2004
  • 资助金额:
    $ 13.22万
  • 项目类别:
Serum Markers /Angiogenesis in von Hippel-Lindau Disease
希佩尔-林道病的血清标志物/血管生成
  • 批准号:
    6784375
  • 财政年份:
    2004
  • 资助金额:
    $ 13.22万
  • 项目类别:
PHENOTYPIC RISK MARKERS IN BRCA1 MUTATION CARRIERS
BRCA1 突变携带者的表型风险标记
  • 批准号:
    6287893
  • 财政年份:
    2001
  • 资助金额:
    $ 13.22万
  • 项目类别:
PHENOTYPIC RISK MARKERS IN BRCA1 MUTATION CARRIERS
BRCA1 突变携带者的表型风险标记
  • 批准号:
    6489436
  • 财政年份:
    2001
  • 资助金额:
    $ 13.22万
  • 项目类别:
GENETIC SUSCEPTIBILITY TO LUNG CANCER
肺癌的遗传易感性
  • 批准号:
    6395788
  • 财政年份:
    2000
  • 资助金额:
    $ 13.22万
  • 项目类别:
GENETIC SUSCEPTIBILITY TO LUNG CANCER
肺癌的遗传易感性
  • 批准号:
    6198626
  • 财政年份:
    1999
  • 资助金额:
    $ 13.22万
  • 项目类别:
GENETIC SUSCEPTIBILITY TO LUNG CANCER
肺癌的遗传易感性
  • 批准号:
    6217475
  • 财政年份:
    1999
  • 资助金额:
    $ 13.22万
  • 项目类别:
GENETIC SUSCEPTIBILITY TO LUNG CANCER
肺癌的遗传易感性
  • 批准号:
    6269752
  • 财政年份:
    1998
  • 资助金额:
    $ 13.22万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.22万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 13.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了